CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT

Rheumatology (Oxford). 2020 Sep 1;59(9):e38-e40. doi: 10.1093/rheumatology/keaa001.

Lucas C M Arruda^{1

2

3}, Emmanuel Clave^{4

5}, Corinne Douay⁴, João R Lima-Júnior^{2

6}, Svetoslav N Slavov², Kelen C R Malmegrim^{2

7}, Antônio José Alberdi^{5

8}, Maria Carolina Oliveira^{1

2

9}, Antoine Toubert^{4

5}

¹ Basic and Applied Immunology Program, Ribeirão Preto Medical School, University of São Paulo.
² Center for Cell-Based Therapy, Regional Hemotherapy Center of the Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
³ Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
⁴ INSERM UMR-1160, Institut de Recherche Saint-Louis, Hôpital Saint-Louis - APHP.
⁵ Université de Paris, Paris, France.
⁶ Graduate Program on Biosciences and Biotechnology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
⁷ Department of Clinical, Toxicological and Bromatological Analysis, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
⁸ Plateforme Technologique, Institut Universitaire d'Hématologie, Paris, France.
⁹ Division of Clinical Immunology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

No abstract available

Publication types